Literature DB >> 17671831

Calcipotriol affects keratinocyte proliferation by decreasing expression of early growth response-1 and polo-like kinase-2.

Jernej Kristl1, Petra Slanc, Metka Krasna, Ales Berlec, Matjaz Jeras, Borut Strukelj.   

Abstract

PURPOSE: Calcipotriol is a potent drug for topical treatment of psoriasis because it manages to inhibit keratinocyte proliferation. In the present study we investigated the effects of calcipotriol on gene expression in human keratinocytes in terms of mechanism of how calcipotriol decreases proliferation.
MATERIALS AND METHODS: Cell proliferation was analyzed by MTT assay. The differential display approach together with qPCR was used to assess the gene expression after treatment. In addition, Western immunoblotting revealed differences on the protein level. Finally, transfection of the KCs with specific small interfering RNA determined the genes necessary to inhibit proliferation.
RESULTS: KCs proliferation was decreased in a concentration-dependent manner. Moreover, calcipotriol dowregulated the expression of two proliferation factors: early growth response-1 (EGR1) and polo-like kinase-2 (PLK2). The protein levels of EGR1 and PLK2 were also decreased. Specific siRNA against EGR1 and PLK2 in KCs resulted in marked reduction of EGR1 and PLK2 expression. In both cases, the reduction resolved in the decreased proliferation of KCs.
CONCLUSION: This study provides a new insight into how calcipotriol affects proliferation of keratinocytes by decreasing the expression of EGR1 and PLK2. Furthermore, the results offer groundwork for developing novel compounds for the treatment of hyperproliferative skin disorders like psoriasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671831     DOI: 10.1007/s11095-007-9388-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

1.  Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin.

Authors:  P Milde; U Hauser; T Simon; G Mall; V Ernst; M R Haussler; P Frosch; E W Rauterberg
Journal:  J Invest Dermatol       Date:  1991-08       Impact factor: 8.551

2.  Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin.

Authors:  Claus Johansen; Esben Flindt; Knud Kragballe; Jeanette Henningsen; Majken Westergaard; Karsten Kristiansen; Lars Iversen
Journal:  J Invest Dermatol       Date:  2005-06       Impact factor: 8.551

3.  Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid.

Authors:  W E Stumpf; M Sar; F A Reid; Y Tanaka; H F DeLuca
Journal:  Science       Date:  1979-12-07       Impact factor: 47.728

4.  Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters.

Authors:  M C Heng; M K Song; J Harker; M K Heng
Journal:  Br J Dermatol       Date:  2000-11       Impact factor: 9.302

Review 5.  Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors.

Authors:  A Gashler; V P Sukhatme
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1995

6.  Polo-like kinase-2 is required for centriole duplication in mammalian cells.

Authors:  Silke Warnke; Stefan Kemmler; Rebecca S Hames; Hsiao-Lun Tsai; Urs Hoffmann-Rohrer; Andrew M Fry; Ingrid Hoffmann
Journal:  Curr Biol       Date:  2004-07-13       Impact factor: 10.834

Review 7.  Aberrant signalling and transcription factor activation as an explanation for the defective growth control and differentiation of keratinocytes in psoriasis: a hypothesis.

Authors:  R C McKenzie; E Sabin
Journal:  Exp Dermatol       Date:  2003-08       Impact factor: 3.960

8.  Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol.

Authors:  John Rømer; Erik Hasselager; Peder Lisby Nørby; Torben Steiniche; Jes Thorn Clausen; Knud Kragballe
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

9.  Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin.

Authors:  C Johansen; K Kragballe; M Rasmussen; T N Dam; L Iversen
Journal:  Br J Dermatol       Date:  2004-09       Impact factor: 9.302

Review 10.  Treatment of psoriasis: role of calcipotriene.

Authors:  R S Kirsner; D Federman
Journal:  Am Fam Physician       Date:  1995-07       Impact factor: 3.292

View more
  4 in total

Review 1.  [Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review].

Authors:  M A Radtke; K Herberger; T Kornek; M Augustin
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

2.  MicroRNA-27a promotes proliferation and suppresses apoptosis by targeting PLK2 in laryngeal carcinoma.

Authors:  Yuan Tian; Shuang Fu; Guang-Bin Qiu; Zhen-Ming Xu; Ning Liu; Xiao-Wen Zhang; Sheng Chen; Ye Wang; Kai-Lai Sun; Wei-Neng Fu
Journal:  BMC Cancer       Date:  2014-09-18       Impact factor: 4.430

Review 3.  Polo-Like Kinase 2: From Principle to Practice.

Authors:  Chuanyong Zhang; Chuangye Ni; Hao Lu
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

4.  Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial.

Authors:  Arash Hossein-nezhad; Avrum Spira; Michael F Holick
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.